Markets:

Overview

News

Currencies

International

Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

6.370 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Friday Markets Coverage ↗

November 19, 2021

Today markets are suffering alongside Austria which locked down against Covid-19 again.

Via Talk Markets

AbCellera Biologics Inc. (ABCL) Q3 2021 Earnings Call Transcript ↗

November 10, 2021

ABCL earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

AbCellera Reports Q3 2021 Business Results

November 09, 2021

From AbCellera Biologics Inc.

Via Business Wire

How Bad Are AbCellera Biologics's Earnings? | Return On Capital Employed ↗

November 09, 2021

Benzinga Pro data, AbCellera Biologics (NASDAQ:ABCL) reported Q2 sales of $27.64 million. Earnings fell to a loss of $7.03 million, resulting in a 104.45% decrease from last...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

AbCellera Announces Virtual Presentations at Investor Conferences in November

November 04, 2021

From AbCellera Biologics Inc.

Via Business Wire

Why AbCellera Biologics Stock Sank 21.6% in October ↗

November 04, 2021

The biotech is now down roughly 56% across 2021's trading.

Via The Motley Fool

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19

November 02, 2021

From AbCellera Biologics Inc.

Via Business Wire

The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies ↗

October 15, 2021

Companies working on sorely needed Covid treatments are innovating to keep up.

Via Investor's Business Daily

AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

October 14, 2021

From AbCellera Biologics Inc.

Via Business Wire

Why AbCellera Biologics Stock Jumped 19.4% Last Month ↗

October 07, 2021

Despite last month's gains, the biotech stock is now down roughly 61% year to date.

Via The Motley Fool

AbCellera, Everest Medicines Team Up To Develop 10 Therapeutic Antibodies ↗

September 23, 2021

AbCellera Biologics Inc (NASDAQ: ABCL) and Everest Medicines Limited have entered into a multi-year collaboration and license agreement to discover...

Via Benzinga

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data ↗

September 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...

Via Benzinga

Cramer's Advice On Ulta Beauty, Laredo Petroleum And More ↗

September 23, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer advised a viewer to buy more Ulta Beauty Inc (NASDAQ: ULTA). He likes the stock very much. Cramer doesn't like...

Via Benzinga

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

September 22, 2021

From AbCellera Biologics Inc.

Via Business Wire

A Day Of Huge Market Moves ↗

September 21, 2021

It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority.

Via Talk Markets

Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

September 21, 2021

From AbCellera Biologics Inc.

Via Business Wire

15 Stocks Moving in Friday's Pre-Market Session ↗

September 17, 2021

Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ABCL) rose 18% to $23.35 in pre-market trading....

Via Benzinga

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold ↗

September 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...

Via Benzinga

AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody ↗

September 17, 2021

The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in...

Via Benzinga

Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19

September 16, 2021

From AbCellera Biologics Inc.

Via Business Wire

Why AbCellera Biologics Stock Jumped 7% on Wednesday ↗

September 15, 2021

The company's drug-development technology is starting to attract attention.

Via The Motley Fool

AbCellera Shares Are Moving Higher On Licensing Pact With Moderna ↗

September 15, 2021

AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for...

Via Benzinga

AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

September 15, 2021

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets

September 13, 2021

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

September 10, 2021

From AbCellera

Via Business Wire

A Weak Week ↗

September 10, 2021

Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants.

Via Talk Markets

Here's Why AbCellera Biologics Stock Gained 10.6% Last Month ↗

September 04, 2021

Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading.

Via The Motley Fool

78 Biggest Movers From Friday ↗

August 16, 2021

Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering. Flora Growth...

Via Benzinga

Why AbCellera Biologics Stock Was Up More Than 17% on Friday ↗

August 13, 2021

The biopharma company's second quarter was better than expected. The future looks pretty bright, too.

Via The Motley Fool

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.